Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ESD | P10768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27844378 | 0.74 | MEN1 (0.40) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL4040438 | 0.72 | MAOB (0.39) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL27580462 | 0.65 | KMT2A (0.44) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL27844393 | 0.64 | PRKCZ (0.31) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL27735036 | 0.64 | KMT2A (0.42) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL4044617 | 0.63 | MAOB (0.35) | MEN1KMT2AHSP90AA1ATMMAOB | |
| SCHEMBL16740593 | 0.63 | PRKCZ (1.00) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL16740643 | 0.61 | PRKCZ (0.78) | MEN1KMT2AHSP90AA1ATMPRKCZ | |
| SCHEMBL17659670 | 0.60 | LMNA (0.47) | GAA | |
| SCHEMBL6292699 | 0.59 | ESD (0.75) | MEN1KMT2AHSP90AA1ATMPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | MEN1 2326/4885KMT2A 990/4885HSP90AA1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.